On Wednesday, Shares of Gilead Sciences Inc. (NASDAQ:GILD), dropped -0.97% to $104.18.
Today, Gilead Sciences, declared pre-clinical data and results from Phase 1 and Phase 2 studies supporting the development of an investigational all-oral, pan-genotypic regimen of Sovaldi® (sofosbuvir 400 mg/SOF), the investigational NS5A inhibitor GS-5816 and GS-9857, an investigational NS3/4A protease inhibitor. These data will be presented at the 50th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress™ 2015) in Vienna, Austria.
In pre-clinical studies, GS-9857 demonstrated similarly potent antiviral activity against HCV replicons of all tested genotypes (1-6), in addition to an improved resistance profile contrast to other HCV protease inhibitors (ePoster #P0899). In a healthy volunteer study, GS-9857 demonstrated a favorable pharmacokinetic profile (ePoster #P0861). Data from a three-day monotherapy study also demonstrated that GS-9857 was well-tolerated and achieved median HCV RNA reductions of more than 3 log10 IU/mL for HCV patients with genotypes 1, 2, 3 and 4 at the 100 mg dose (ePoster #P0901).
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Shares of W&T Offshore Inc. (NYSE:WTI), declined -0.95% to $6.27, during its last trading session.
W&T Offshore, participated in the IPAA Oil & Gas Investor Symposium held from April 20-22, 2015 in New York.
Tracy Krohn, W&T’s Chairman and CEO, made a presentation on Tuesday, April 21st at 4:30 p.m. Eastern Time (3:30 pm Central Time).
W&T Offshore, Inc., an independent oil and natural gas producer, together with its auxiliaries, engages in the acquisition, exploration, and development of oil and natural gas properties primarily in the Gulf of Mexico and onshore in the Permian Basin of West Texas. It holds working interests in about 63 offshore fields in federal and state waters.
At the end of Wednesday’s trade, Shares of SUPERVALU Inc. (NYSE:SVU), dwindled -0.90% to $11.01.
SUPERVALU, will hold its fiscal 2015 fourth quarter conference call on Tuesday April 28, 2015 at 9:00 a.m. Central time. A replay of the conference call will be archived on SUPERVALU’s website under “Investors, Presentations and Webcasts.”
SUPERVALU INC., together with its auxiliaries, operates as a wholesale distributor to independent retail customers in the United States. It operates in three segments: Retail Food, Save-A-Lot, and Independent Business.
Finally, Hawaiian Holdings Inc. (NASDAQ:HA), ended its last trade with -0.90% loss, and closed at $22.02.
Hawaiian Holdings, plans to report its first quarter 2015 financial results after the market closes on Thursday, April 23, 2015. An investor conference call is planned at 4:30 p.m. Eastern Time.
The call will be open to all interested investors through a live audio webcast accessible in the Investor Relations section of Hawaiian’s website at HawaiianAirlines.com. For those who are not able to listen to the live webcast, the call will be archived for 90 days on Hawaiian’s website.
Hawaiian Holdings, Inc., through its partner, Hawaiian Airlines, Inc., engages in the planned air transportation of passengers and cargo. It offers daily services on North America routes between the state of Hawaii and Los Angeles, Oakland, Sacramento, San Diego, San Francisco, and San Jose, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
